Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.42 USD
Change Today +0.21 / 1.87%
Volume 424.9K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$11.10
Previous Close
$11.21
Day High
$11.43
Day Low
$11.03
52 Week High
07/20/15 - $16.83
52 Week Low
03/26/15 - $7.85
Market Cap
836.4M
Average Volume 10 Days
898.4K
EPS TTM
$-0.38
Shares Outstanding
73.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

50 Employees
Last Reported Date: 03/2/15
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $633.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $461.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $503.8K
Senior Vice President of Drug Discovery
Total Annual Compensation: $460.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2014.

biocryst pharmaceuticals inc (BCRX) Key Developments

BioCryst Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Provides Net Operating Cash Use Outlook for the Year 2015

BioCryst Pharmaceuticals, Inc. reported unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company’s total revenues were $25,842,000 against $1,466,000 a year ago. Profit from operations was $5,342,000 against loss of $11,619,000 a year ago. Net income was $4,901,000 or $0.06 per diluted share against loss of $14,649,000 or $0.23 per diluted share a year ago. Revenue increase in the quarter was primarily due to the partial recognition of the upfront payment to BioCryst resulting from the licensing of RAPIVAB® (peramivir injection), as well as a significant increase in collaboration revenue associated with BCX4430 development as a medical countermeasure for Ebola virus and other filovirus diseases. Net operating cash use for the second quarter of 2015 was $12.0 million, as compared to $6.8 million for the second quarter of 2014. For the six months, the company’s total revenues were $32,668,000 against $4,924,000 a year ago. Loss from operations was $9,088,000 against 19,005,000 a year ago. Net loss was $10,263,000 or $0.14 per diluted share against $24,786,000 or $0.40 per diluted share a year ago. Net operating cash use for the first six months of 2015 was $15.8 million as compared to $11.8 million for the 2014 period. Based upon development plans and assumptions and its awarded government contracts, the company expects its 2015 net operating cash use to be in the range of $18 to $28 million upon adjusting its previously predicted range for the first six month results, including the $33.7 million upfront payment from bioCSL, and expects its 2015 operating expenses to continue to be in the range of $75 to $95 million.

BioCryst Pharmaceuticals, Inc. Appoints Robert A. Ingram as Board of Director

BioCryst Pharmaceuticals, Inc. announced that Robert A. Ingram was elected to the company's Board of Directors. Bob Ingram joined Hatteras Venture Partners as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome.

BioCryst Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 07, 2015

BioCryst Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $11.42 USD +0.21

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,310 JPY +57.00
Dyax Corp $23.69 USD -0.20
GlaxoSmithKline PLC 1,341 GBp +9.50
Pharming Group NV €0.31 EUR -0.006
Shire PLC 5,025 GBp +10.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.1x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.